KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Operating Expenses (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Operating Expenses for 16 consecutive years, with $919.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 56.88% year-over-year to $919.2 million, compared with a TTM value of $2.8 billion through Dec 2025, up 18.66%, and an annual FY2025 reading of $2.8 billion, up 18.66% over the prior year.
  • Operating Expenses was $919.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $822.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $919.2 million in Q4 2025 and bottomed at $382.0 million in Q1 2022.
  • Average Operating Expenses over 5 years is $564.2 million, with a median of $541.3 million recorded in 2023.
  • The sharpest move saw Operating Expenses fell 17.12% in 2022, then surged 56.88% in 2025.
  • Year by year, Operating Expenses stood at $515.7 million in 2021, then rose by 6.77% to $550.6 million in 2022, then increased by 12.4% to $618.9 million in 2023, then decreased by 5.34% to $585.9 million in 2024, then soared by 56.88% to $919.2 million in 2025.
  • Business Quant data shows Operating Expenses for BMRN at $919.2 million in Q4 2025, $822.8 million in Q3 2025, and $548.5 million in Q2 2025.